Title: Deep Learning-based CT Radiomics Predicts Prognosis of Unresectable Hepatocellular
Carcinoma Treated with TACE-HAIC combined with PD-1 Inhibitors and Tyrosine Kinase
Inhibitors
Version: 2 Date: 06 Oct 2024
Reviewer's report:
- Line 48: The term "uHCC" appears twice.
- Line 69: What is the stage of HCC in this study?
- Line 124: Toripalimab does not have an indication for liver cancer treatment, so why is it
included in this study? Additionally, the usual dose for toripalimab is 240 mg.
- Line 126: Is the combination therapy discussed in this study intended for first-line treatment?
Why is a second-line therapy mentioned here?
- Line 183: Why did you construct a nomogram for PFS only and not for OS?
- Lines 138-140: You mention safety evaluation indicators, but there are no related data in the
results section. The authors need to supplement this information.
- Line 215: It is recommended to use either "HCC" or "Liver Cancer" consistently throughout
the paper. Additionally, the total number of participants in this study is 122; does this include
external validation data? Please verify.
- Line 227: If there are 118 people still alive at the last follow-up, this does not match the OS
curve. Please check the data.
- Lines 228-230: Please verify the survival rate data.
- Is the unit for "Largest Tumor Diameter" in Table 1 centimeter? Please confirm.
- The term "tumor thrombus" would be more appropriate for referring to cancer embolus.
- When was the mRECIST standard evaluation conducted post-treatment? Please include this
in the footnotes of Table 1.
Title: Deep Learning-based CT Radiomics Predicts Prognosis of Unresectable Hepatocellular
Carcinoma Treated with TACE-HAIC combined with PD-1 Inhibitors and Tyrosine Kinase
Inhibitors
Version: 2 Date: 06 Oct 2024
Reviewer's report:
- Line 48: The term "uHCC" appears twice.
- Line 69: What is the stage of HCC in this study?
- Line 124: Toripalimab does not have an indication for liver cancer treatment, so why is it
included in this study? Additionally, the usual dose for toripalimab is 240 mg.
- Line 126: Is the combination therapy discussed in this study intended for first-line treatment?
Why is a second-line therapy mentioned here?
- Line 183: Why did you construct a nomogram for PFS only and not for OS?
- Lines 138-140: You mention safety evaluation indicators, but there are no related data in the
results section. The authors need to supplement this information.
- Line 215: It is recommended to use either "HCC" or "Liver Cancer" consistently throughout
the paper. Additionally, the total number of participants in this study is 122; does this include
external validation data? Please verify.
- Line 227: If there are 118 people still alive at the last follow-up, this does not match the OS
curve. Please check the data.
- Lines 228-230: Please verify the survival rate data.
- Is the unit for "Largest Tumor Diameter" in Table 1 centimeter? Please confirm.
- The term "tumor thrombus" would be more appropriate for referring to cancer embolus.
- When was the mRECIST standard evaluation conducted post-treatment? Please include this
in the footnotes of Table 1.
Please review this paper.
user
Title: Deep Learning-based CT Radiomics Predicts Prognosis of Unresectable Hepatocellular
Carcinoma Treated with TACE-HAIC combined with PD-1 Inhibitors and Tyrosine Kinase
Inhibitors
Version: 2 Date: 06 Oct 2024
Reviewer's report:
- Line 48: The term "uHCC" appears twice.
- Line 69: What is the stage of HCC in this study?
- Line 124: Toripalimab does not have an indication for liver cancer treatment, so why is it
included in this study? Additionally, the usual dose for toripalimab is 240 mg.
- Line 126: Is the combination therapy discussed in this study intended for first-line treatment?
Why is a second-line therapy mentioned here?
- Line 183: Why did you construct a nomogram for PFS only and not for OS?
- Lines 138-140: You mention safety evaluation indicators, but there are no related data in the
results section. The authors need to supplement this information.
- Line 215: It is recommended to use either "HCC" or "Liver Cancer" consistently throughout
the paper. Additionally, the total number of participants in this study is 122; does this include
external validation data? Please verify.
- Line 227: If there are 118 people still alive at the last follow-up, this does not match the OS
curve. Please check the data.
- Lines 228-230: Please verify the survival rate data.
- Is the unit for "Largest Tumor Diameter" in Table 1 centimeter? Please confirm.
- The term "tumor thrombus" would be more appropriate for referring to cancer embolus.
- When was the mRECIST standard evaluation conducted post-treatment? Please include this
in the footnotes of Table 1.
assistant